These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24628049)

  • 1. Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition.
    God JM; Zhao D; Cameron CA; Amria S; Bethard JR; Haque A
    Immunology; 2014 Jul; 142(3):492-505. PubMed ID: 24628049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA class II defects in Burkitt lymphoma: bryostatin-1-induced 17 kDa protein restores CD4+ T-cell recognition.
    Hossain A; God JM; Radwan FF; Amria S; Zhao D; Bethard JR; Haque A
    Clin Dev Immunol; 2011; 2011():780839. PubMed ID: 22162713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors.
    God JM; Cameron C; Figueroa J; Amria S; Hossain A; Kempkes B; Bornkamm GW; Stuart RK; Blum JS; Haque A
    J Immunol; 2015 Feb; 194(4):1434-45. PubMed ID: 25595783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs.
    Khanna R; Burrows SR; Thomson SA; Moss DJ; Cresswell P; Poulsen LM; Cooper L
    J Immunol; 1997 Apr; 158(8):3619-25. PubMed ID: 9103423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAMP-2-deficient human B cells exhibit altered MHC class II presentation of exogenous antigens.
    Crotzer VL; Glosson N; Zhou D; Nishino I; Blum JS
    Immunology; 2010 Nov; 131(3):318-30. PubMed ID: 20518820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation.
    Hegde NR; Tomazin RA; Wisner TW; Dunn C; Boname JM; Lewinsohn DM; Johnson DC
    J Virol; 2002 Nov; 76(21):10929-41. PubMed ID: 12368336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.
    Kremer AN; van der Meijden ED; Honders MW; Goeman JJ; Wiertz EJ; Falkenburg JH; Griffioen M
    Blood; 2012 Oct; 120(16):3246-55. PubMed ID: 22889757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of the LFA-3 adhesion pathway in Burkitt's lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition.
    Griffin H; Rowe M; Murray R; Brooks J; Rickinson A
    Eur J Immunol; 1992 Jul; 22(7):1741-8. PubMed ID: 1378014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma.
    Goldstein OG; Hajiaghamohseni LM; Amria S; Sundaram K; Reddy SV; Haque A
    Cancer Immunol Immunother; 2008 Oct; 57(10):1461-70. PubMed ID: 18343923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-covalent presentation of sulfamethoxazole to human CD4+ T cells is independent of distinct human leucocyte antigen-bound peptides.
    Burkhart C; Britschgi M; Strasser I; Depta JP; von Greyerz S; Barnaba V; Pichler WJ
    Clin Exp Allergy; 2002 Nov; 32(11):1635-43. PubMed ID: 12569986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
    Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
    Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells.
    Frisan T; Zhang QJ; Levitskaya J; Coram M; Kurilla MG; Masucci MG
    Int J Cancer; 1996 Oct; 68(2):251-8. PubMed ID: 8900437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms regulating enhanced human leukocyte antigen class II-mediated CD4 + T cell recognition of human B-cell lymphoma by resveratrol.
    Radwan FF; Zhang L; Hossain A; Doonan BP; God JM; Haque A
    Leuk Lymphoma; 2012 Feb; 53(2):305-14. PubMed ID: 21854084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design.
    Herrera OB; Brett S; Lechler RI
    Vaccine; 2002 Dec; 21(3-4):231-42. PubMed ID: 12450698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luminal bacterial antigen-specific CD4+ T-cell responses in HLA-B27 transgenic rats with chronic colitis are mediated by both major histocompatibility class II and HLA-B27 molecules.
    Qian BF; Tonkonogy SL; Balfour Sartor R
    Immunology; 2006 Mar; 117(3):319-28. PubMed ID: 16476051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of class I major histocompatibility complex antigens in Epstein-Barr virus-carrying lymphoblastoid cell lines and Burkitt lymphoma cells.
    Jilg W; Voltz R; Markert-Hahn C; Mairhofer H; Münz I; Wolf H
    Cancer Res; 1991 Jan; 51(1):27-32. PubMed ID: 1899042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant expression of HLA class-I antigens in Burkitt lymphoma cells.
    Andersson ML; Stam NJ; Klein G; Ploegh HL; Masucci MG
    Int J Cancer; 1991 Feb; 47(4):544-50. PubMed ID: 1899854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide binding and antigen presentation by class II histocompatibility glycoproteins.
    Jensen PE
    Biopolymers; 1997; 43(4):303-22. PubMed ID: 9316394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.